Free Newsletter
Novartis plots $700M biotech plant
Free newsletter via e-mail
Tools
Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. More than 300 people are expected to work there when it's complete in 2012.
It's Novartis' second big investment in Singapore manufacturing. The company just opened a new $180 million tabletting plant there today; it's expected to employ some 160 workers. Singapore was featured twice on our annual list of the top five regions attracting biotech business.
- check out the report from Channel News Asia
Related Articles:
Novartis injects $816.5M in vaccine plant. Report
Singapore to spend $8B on biotech R&D. Report
GSK opens $13M drug discovery lab in Singapore. Report
Singapore to spend $8B on biotech R&D. Report
GSK blueprints $190M vaccine plant for Singapore. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
